Market Overview

Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results

Share:

Alnylam
Pharmaceuticals, Inc.
(NASDAQ:ALNY), the leading RNAi therapeutics
company, announced today that it will report financial results for the
second quarter ending June 30, 2018 on Thursday, August 2, 2018, before
the U.S. financial markets open.

Management will provide an update on the Company and discuss second
quarter 2018 results as well as expectations for the future via
conference call on Thursday, August 2, 2018 at 8:30 am ET. To access the
call, please dial 877-312-7507 (domestic) or 631-813-4828
(international) five minutes prior to the start time and refer to
conference ID 1365915. A replay of the call will be available beginning
at 11:30 am ET on the day of the call. To access the replay, please dial
855-859-2056 (domestic) or 404-537-3406 (international) and refer to
conference ID 1365915.

A live audio webcast of the call will be available on the Investors
section of the Company's website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event.

About Alnylam Pharmaceuticals
Alnylam (NASDAQ:ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of people afflicted with rare genetic, cardio-metabolic, and hepatic
infectious diseases. Based on Nobel Prize-winning science, RNAi
therapeutics represent a powerful, clinically validated approach for the
treatment of a wide range of severe and debilitating diseases. Founded
in 2002, Alnylam is delivering on a bold vision to turn scientific
possibility into reality, with a robust discovery platform and deep
pipeline of investigational medicines, including four product candidates
that are in late-stage development. Looking forward, Alnylam will
continue to execute on its "Alnylam 2020" strategy of building a
multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines to address the needs of
patients who have limited or inadequate treatment options. Alnylam
employs over 800 people in the U.S. and Europe and is headquartered in
Cambridge, MA. For more information about our people, science and
pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.

View Comments and Join the Discussion!